Tenax Therapeutics (NASDAQ:TENX) Now Covered by StockNews.com

StockNews.com began coverage on shares of Tenax Therapeutics (NASDAQ:TENX) in a research note published on Friday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

TENX has been the topic of a number of other reports. William Blair reiterated an “outperform” rating on shares of Tenax Therapeutics in a research note on Monday, March 10th. Leerink Partners set a $20.00 price objective on Tenax Therapeutics in a research note on Monday, March 10th. One research analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $18.00.

Tenax Therapeutics Trading Up 2.2 %

NASDAQ:TENX opened at $6.57 on Friday. Tenax Therapeutics has a 52-week low of $2.77 and a 52-week high of $7.89. The business’s fifty day moving average is $6.44 and its 200 day moving average is $5.35.

Hedge Funds Weigh In On Tenax Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC increased its stake in Tenax Therapeutics by 32.4% in the 4th quarter. Geode Capital Management LLC now owns 24,354 shares of the specialty pharmaceutical company’s stock worth $151,000 after acquiring an additional 5,964 shares during the last quarter. Two Sigma Investments LP bought a new position in Tenax Therapeutics in the 4th quarter worth about $84,000. Millennium Management LLC bought a new position in Tenax Therapeutics in the 4th quarter worth about $166,000. Sphera Funds Management LTD. bought a new position in Tenax Therapeutics in the 3rd quarter worth about $101,000. Finally, Stonepine Capital Management LLC bought a new position in Tenax Therapeutics in the 3rd quarter worth about $173,000. 1.67% of the stock is currently owned by institutional investors.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.